Overview

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
A placebo controlled study of the impact on insulin sensitivity and lipid profile of maraviroc 300 mg twice daily in HIV negative male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
St Stephens Aids Trust
Treatments:
Maraviroc